Skip to content

Erdafitinib

Balversa (erdafitinib) is a small molecule pharmaceutical. Erdafitinib was first approved as Balversa on 2019-04-12. It is used to treat transitional cell carcinoma in the USA. It is known to target fibroblast growth factor receptor 2, fibroblast growth factor receptor 4, vascular endothelial growth factor receptor 2, fibroblast growth factor receptor 1, and fibroblast growth factor receptor 3. Balversa's patents are valid until 2038-02-02 (FDA).
Trade Name Balversa
Common Name Erdafitinib
Indication transitional cell carcinoma
Drug Class Tyrosine kinase inhibitors
Erdafitinib
Get full access now